What the FDA labels say about taking them together
Carbamazepine and dolutegravir
Dolutegravir's FDA label of May 22, 2026 names carbamazepine in its drug interactions section; the carbamazepine labels PlainMeds reads (3) do not name dolutegravir. The dolutegravir label: “… TIVICAY PD to twice daily. Use alternative treatment that does not include carbamazepine where possible for INSTI-experienced patients with certain INSTI-associated resistance substitutions or clinically suspected INSTI …”
Check it at the source: the carbamazepine FDA label on DailyMed (effective August 20, 2026, Novartis Pharmaceuticals Corporation); the dolutegravir FDA label on DailyMed (effective May 22, 2026, ST. MARY'S MEDICAL PARK PHARMACY).
What does the carbamazepine label say about dolutegravir?
Carbamazepine's label (effective August 20, 2026) and its 2 other brand-application labels do not name dolutegravir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Tegretol), Novartis Pharmaceuticals Corporation, effective August 20, 2026 (SPL set 8d409411-aa9f-4f3a-a52c-fbcb0c3ec053), via openFDA; the full label on DailyMed
What does the dolutegravir label say about carbamazepine?
Dolutegravir label, drug interactionsConcomitant Drug Class/Drug Name: Carbamazepine a; Effect on Concentration of Dolutegravir and/or Concomitant Drug: ↓Dolutegravir; Clinical Comment: Adjust dose of TIVICAY to twice daily in treatment-naïve or treatment-experienced, INSTI-naïve adult patients. In pediatric patients, increase the weight-based dose of TIVICAY or TIVICAY PD to twice daily (Tables,, and). Use alternative treatment that does not include carbamazepine where possible for INSTI-experienced patients with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance. b
Source: FDA drug label (Tivicay Pd, NDA213983), ViiV Healthcare Company, effective August 25, 2026 (SPL set 63df5af3-b8ac-4e76-9830-2dbb340af922), via openFDA
Source: FDA drug label (Tivicay), NDA204790 (Viiv Hlthcare), as published by ST. MARY'S MEDICAL PARK PHARMACY, effective May 22, 2026 (SPL set 485bc9db-8665-9f5a-e063-6394a90a7921), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Carbamazepine | Dolutegravir | |
|---|---|---|
| Labeled for | Bipolar disorder, Seizures and epilepsy | HIV |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.119 per tablet 200 mg tablet | $77.64 per tablet 50 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once